Nyla A. Heerema

Nyla A. Heerema's AcademicInfluence.com Rankings

Nyla A. Heerema

Mathematics

#6974

World Rank

#9569

Historical Rank

Measure Theory

#1768

World Rank

#2168

Historical Rank

mathematics Degrees

Download Badge

Mathematics

Why Is Nyla A. Heerema Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Nyla A. Heerema's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. (2013) (1980)
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. (2014) (1029)
Multiplex PCR: critical parameters and step-by-step protocol. (1997) (989)
Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. (1996) (881)
Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. (2009) (654)
Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. (2015) (626)
The genomic landscape of hypodiploid acute lymphoblastic leukemia (2013) (585)
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL (2018) (575)
Rearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemia (2009) (574)
THE GENOMIC LANDSCAPE OF PEDIATRIC AND YOUNG ADULT T-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA (2017) (569)
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. (2010) (554)
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. (2015) (492)
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. (2004) (460)
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine (2010) (458)
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. (2014) (446)
Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). (2007) (432)
Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. (2007) (404)
Cytogenetics in acute leukemia (2004) (400)
Clinical implications of FLT3 mutations in pediatric AML. (2006) (395)
Prognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia. (2012) (386)
Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group Study AALL0031 (2014) (342)
Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. (2003) (337)
Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. (1993) (335)
Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. (2018) (325)
Cytogenetics in acute leukemia. (2004) (315)
Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. (2007) (310)
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. (2006) (303)
Hematologic neoplasia associated with primary mediastinal germ-cell tumors. (1990) (302)
Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. (2015) (289)
Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. (2006) (276)
Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. (2008) (276)
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. (2006) (260)
Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. (2008) (257)
Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group Study AALL0232. (2016) (256)
Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. (2007) (256)
BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. (2017) (239)
Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. (2009) (238)
Racial and ethnic differences in survival of children with acute lymphoblastic leukemia. (2002) (231)
Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. (2009) (225)
Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia (2014) (224)
Expression of dominant-negative and mutant isoforms of the antileukemic transcription factor Ikaros in infant acute lymphoblastic leukemia. (1999) (220)
Improvements in cytogenetic slide preparation: controlled chromosome spreading, chemical aging and gradual denaturing. (2001) (216)
Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. (2017) (214)
Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: a report from the children's cancer group. (1999) (207)
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. (2009) (196)
Maternal Diet and Infant Leukemia: The DNA Topoisomerase II Inhibitor Hypothesis: A Report from the Children's Oncology Group (2005) (186)
Klinefelter's syndrome associated with mediastinal germ cell neoplasms. (1987) (185)
Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. (1999) (185)
Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (> 50 chromosomes). (2000) (182)
Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. (2014) (181)
The genetic basis and cell of origin of mixed phenotype acute leukaemia (2018) (171)
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. (2009) (170)
Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. (1998) (170)
Update on late relapse of germ cell tumor: a clinical and molecular analysis. (2003) (168)
Epigenetic Profiling in Chronic Lymphocytic Leukemia Reveals Novel Methylation Targets (2004) (167)
Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. (2010) (165)
An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome (2014) (163)
The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. (2009) (157)
Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group. (1998) (150)
Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622. (2018) (150)
Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. (2012) (144)
Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study. (2005) (140)
Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. (2007) (138)
Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. (2012) (134)
Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. (2002) (133)
Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. (2011) (132)
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. (2011) (131)
Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. (2015) (131)
Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity. (1989) (129)
Improved Survival for Children and Young Adults With T-Lineage Acute Lymphoblastic Leukemia: Results From the Children's Oncology Group AALL0434 Methotrexate Randomization. (2018) (129)
Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies (1998) (127)
Clinical significance of MLL-AF4 fusion transcript expression in the absence of a cytogenetically detectable t(4;11)(q21;q23) chromosomal translocation. (1998) (125)
Therapeutic leukapheresis in hyperleucocytic leukaemias: lack of correlation between degree of cytoreduction and early mortality rate (1997) (123)
Precancerous Stem Cells Have the Potential for both Benign and Malignant Differentiation (2006) (118)
Association of chromosome arm 9p abnormalities with adverse risk in childhood acute lymphoblastic leukemia: A report from the Children's Cancer Group. (1999) (118)
Gene expression profiles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children's Oncology Group study. (2012) (117)
Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. (2017) (116)
Intrachromosomal amplification of chromosome 21 is associated with inferior outcomes in children with acute lymphoblastic leukemia treated in contemporary standard-risk children's oncology group studies: a report from the children's oncology group. (2013) (116)
Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. (2012) (112)
Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. (2010) (109)
Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from cancer and leukemia group B study 8461. (2004) (108)
A Multi-Institutional Phase II Study of the Efficacy and Tolerability of Lapatinib in Patients with Advanced Hepatocellular Carcinomas (2009) (108)
TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children. (2018) (106)
Frequency and clinical significance of cytogenetic abnormalities in pediatric T-lineage acute lymphoblastic leukemia: a report from the Children's Cancer Group. (1998) (106)
Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group. (2006) (102)
Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab. (2003) (98)
Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia (2009) (97)
A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. (2014) (95)
Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group. (2009) (93)
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study (2020) (91)
Specific extra chromosomes occur in a modal number dependent pattern in pediatric acute lymphoblastic leukemia (2007) (89)
Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome (2004) (86)
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia. (2018) (85)
Expression of HOX11 in childhood T-lineage acute lymphoblastic leukaemia can occur in the absence of cytogenetic aberration at 10q24: a study from the Children's Cancer Group (CCG) (2003) (84)
Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial. (2010) (83)
Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. (2010) (81)
Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (2016) (80)
Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4. (2014) (80)
Mll partial tandem duplication and Flt3 internal tandem duplication in a double knock-in mouse recapitulates features of counterpart human acute myeloid leukemias. (2012) (80)
Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group. (2018) (79)
Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG‐1952 (2005) (77)
Hypoplastic myelodysplastic syndromes can be distinguished from acquired aplastic anemia by CD34 and PCNA immunostaining of bone marrow biopsy specimens. (1997) (77)
Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children's Oncology Group. (2011) (77)
Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. (2009) (76)
Children's Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia. (2020) (75)
A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. (2012) (74)
Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331. (2019) (73)
Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T‐cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434 (2015) (72)
Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience. (2008) (71)
The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience (2016) (71)
Posttransplantation lymphoproliferative disorders in bone marrow transplant recipients are aggressive diseases with a high incidence of adverse histologic and immunobiologic features. (1997) (70)
Intensified chemotherapy without SCT in infant ALL: Results from COG P9407 (Cohort 3) (2015) (70)
Molecular analysis of infant acute lymphoblastic leukemia: MLL gene rearrangement and reverse transcriptase-polymerase chain reaction for t(4; 11)(q21; q23). (1995) (69)
A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism. (2004) (68)
Deregulated CDC25A expression promotes mammary tumorigenesis with genomic instability. (2007) (67)
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial (2020) (67)
Deletion of 7p or monosomy 7 in pediatric acute lymphoblastic leukemia is an adverse prognostic factor: a report from the Children's Cancer Group (2004) (66)
Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. (2011) (65)
Hematopoietic precursor cells within the yolk sac tumor component are the source of secondary hematopoietic malignancies in patients with mediastinal germ cell tumors (1993) (64)
WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group. (2010) (63)
The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study (2011) (62)
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia (2012) (62)
Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma (2010) (62)
Resistance to the Translation Initiation Inhibitor Silvestrol is Mediated by ABCB1/P-Glycoprotein Overexpression in Acute Lymphoblastic Leukemia Cells (2011) (61)
Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia. (2013) (60)
Development and Validation Of a Highly Sensitive and Specific Gene Expression Classifier To Prospectively Screen and Identify B-Precursor Acute Lymphoblastic Leukemia (ALL) Patients With a Philadelphia Chromosome-Like (“Ph-like” or “BCR-ABL1-Like”) Signature For Therapeutic Targeting and Clinical In (2013) (59)
Allogeneic bone marrow transplantation in first remission for children with ultra-high-risk features of acute lymphoblastic leukemia: A children's oncology group study report. (2007) (59)
Common chromosome fragile sites in human and murine epithelial cells and FHIT/FRA3B loss‐induced global genome instability (2013) (58)
Delineation of the minimal commonly deleted segment and identification of candidate tumor‐suppressor genes in del(9q) acute myeloid leukemia (2005) (57)
Complex karyotype predicts for inferior outcomes following reduced‐intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia (2012) (56)
COG AALL0434: A randomized trial testing nelarabine in newly diagnosed t-cell malignancy. (2018) (56)
Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: long-term follow-up of patients treated on Children's Cancer Group Trial 1881. (2003) (56)
Chromosome Abnormalities May Correlate With Prognosis in Burkitt/Burkitt-Like Lymphomas of Children and Adolescents: A Report From Children's Cancer Group Study CCG-E08 (2004) (55)
Complete response to induction therapy in patients with Myc‐positive and double‐hit non‐Hodgkin lymphoma is associated with prolonged progression‐free survival (2014) (55)
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2017) (55)
A single‐institution retrospective cohort study of first‐line R‐EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor (2018) (54)
Rearrangement of CRLF 2 in B-progenitor – and Down syndrome – associated acute lymphoblastic leukemia (2009) (54)
SNRPN methylation patterns in germ cell tumors as a reflection of primordial germ cell development (2001) (54)
An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children’s Oncology Group study CCG‐5961 (2010) (54)
Establishment in long term culture of megakaryocytic leukemia cells (EST-IU) from the marrow of a patient with leukemia and a mediastinal germ cell neoplasm. (1986) (51)
Impact of Initial CSF Findings on Outcome Among Patients With National Cancer Institute Standard- and High-Risk B-Cell Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. (2017) (50)
Genetic variants modify susceptibility to leukemia in infants: A Children's Oncology Group report (2013) (50)
Periconceptional vitamin use and leukemia risk in children with Down syndrome (2005) (49)
Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles (2011) (49)
Stimulation of chronic lymphocytic leukemia cells with CpG oligodeoxynucleotide gives consistent karyotypic results among laboratories: a CLL Research Consortium (CRC) Study. (2010) (49)
Final results of EFC6663: a multicenter, international, phase 2 study of alvocidib for patients with fludarabine-refractory chronic lymphocytic leukemia. (2015) (49)
The myeloproliferative reaction in a child with down syndrome: Cytological and chromosomal evidence for a transient leukemia (1981) (49)
Chromosome abnormalities in advanced stage lymphoblastic lymphoma of children and adolescents: a report from CCG-E08. (2007) (49)
Amplification of distant estrogen response elements deregulates target genes associated with tamoxifen resistance in breast cancer. (2013) (48)
B-cell growth factor receptor expression and B-cell growth factor response of leukemic B cell precursors and B lineage lymphoid progenitor cells (1987) (48)
Characterization of a New Chronic Lymphocytic Leukemia Cell Line for Mechanistic In Vitro and In Vivo Studies Relevant to Disease (2013) (48)
Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: A report from the Children's Oncology Group (2011) (48)
Leukaemic transformation of engrafted bone marrow cells (1985) (47)
T-cell prolymphocytic leukemia: an aggressive T cell malignancy with frequent cutaneous tropism. (2006) (46)
Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features (2012) (45)
Poor treatment outcome of Philadelphia chromosome-positive pediatric acute lymphoblastic leukemia despite intensive chemotherapy. (1999) (44)
Dicentric (9;20)(p11;q11) identified by fluorescence in situ hybridization in four pediatric acute lymphoblastic leukemia patients. (1996) (42)
KRAS2 oncogene overexpression in myelodysplastic syndrome with translocation 5;12. (1988) (42)
Comparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexate plus asparaginase (C-MTX/ASNase) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children's Oncology Group Study AALL0232. (2011) (42)
Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia (2014) (41)
Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: results from Children’s Oncology Group Study AALL0031 (2014) (41)
Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia. (2020) (40)
Comparison of Results from a Phase 1/2 Study of Lumiliximab (Anti-CD23) in Combination with FCR for Patients with Relapsed CLL with Published FCR Results. (2006) (40)
Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia (2005) (40)
Evidence for the clonal nature of hypereosinophilic syndrome. (1988) (39)
Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study. (2011) (39)
Clinical Significance of Deletions of Chromosome Arm 6q in Childhood Acute Lymphoblastic Leukemia: A Report from the Children's Cancer Group (2000) (39)
A prospective comparison of UroVysion FISH and urine cytology in bladder cancer detection (2017) (39)
Improved Early Event Free Survival (EFS) in Children with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) with Intensive Imatinib in Combination with High Dose Chemotherapy: Children’s Oncology Group (COG) Study AALL0031. (2007) (38)
Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children’s Oncology Group (COG) (2017) (36)
Hematopoietic Stem-Cell Transplantation Does Not Improve the Poor Outcome of Children With Hypodiploid Acute Lymphoblastic Leukemia: A Report From Children's Oncology Group. (2019) (36)
Wwox–Brca1 interaction: role in DNA repair pathway choice (2016) (36)
Primary Follicular Lymphoma of the Testis in Children and Adolescents (2012) (36)
Abnormalities of chromosome bands 13q12 to 13q14 in childhood acute lymphoblastic leukemia. (2000) (36)
Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials (2018) (36)
Enhanced detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide in combination with pokeweed mitogen and phorbol myristate acetate. (2011) (36)
Triple-color FISH analysis of 12p amplification in testicular germ-cell tumors using 12p band-specific painting probes (1998) (35)
Excess congenital non-synonymous variation in leukemia-associated genes in MLL− infant leukemia: a Children's Oncology Group report (2013) (35)
Childhood and maternal infections and risk of acute leukaemia in children with Down syndrome: a report from the Children's Oncology Group (2004) (35)
MLL Rearrangements Impact Outcome in HOXA-deregulated T-lineage Acute Lymphoblastic Leukemia: A Children's Oncology Group Study (2016) (35)
Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high‐risk stratum of patients with newly diagnosed high‐risk B‐lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131 (2018) (35)
Different lineages of P1A-expressing cancer cells use divergent modes of immune evasion for T-cell adoptive therapy. (2006) (34)
CD34 immunostaining of bone marrow biopsy specimens is a reliable way to classify the phases of chronic myeloid leukemia. (1994) (34)
Colour-changing karyotyping: an alternative to M-FISH/SKY (1999) (34)
Flow cytometric immunophenotypic characterization of pediatric and adult minimally differentiated acute myeloid leukemia (AML-M0). (2000) (33)
Maternal exposure to household chemicals and risk of infant leukemia: a report from the Children’s Oncology Group (2011) (33)
Frequency, molecular pathology and potential clinical significance of partial chromosome 3 aberrations in uveal melanoma (2011) (33)
Prevalence and clinical implications of NRAS mutations in childhood AML: a report from the Children's Oncology Group (2011) (31)
The genomic landscape of pediatric acute lymphoblastic leukemia (2022) (31)
Clinical findings in patients with marker chromosomes identified by fluorescence in situ hybridization (1993) (31)
Inherited genetic susceptibility of acute lymphoblastic leukemia in Down syndrome. (2019) (31)
BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: A report from the Children's Oncology Group (2014) (31)
MicroRNA Profiles of Drug-Resistant Myeloma Cell Lines (2010) (30)
Expression of BCR-ABL, E2A-PBX1, and MLL-AF4 fusion transcripts in newly diagnosed children with acute lymphoblastic leukemia: a Children's Cancer Group initiative. (1997) (30)
Integration of cytogenomic data for furthering the characterization of pediatric B-cell acute lymphoblastic leukemia: a multi-institution, multi-platform microarray study. (2015) (30)
Frequent p53 overexpression in therapy related myelodysplastic syndromes and acute myeloid leukemias: an immunohistochemical study of bone marrow biopsies. (1993) (29)
Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib. (2017) (29)
Maternal prenatal cigarette, alcohol and illicit drug use and risk of infant leukaemia: a report from the Children's Oncology Group. (2011) (28)
Abnormalities of chromosome bands 15q13‐15 in childhood acute lymphoblastic leukemia (2002) (28)
Masked hypodiploidy: Hypodiploid acute lymphoblastic leukemia (ALL) mimicking hyperdiploid ALL in children: A report from the Children's Oncology Group. (2019) (28)
Fragile sites induced by FUdR, caffeine, and aphidicolin (2004) (28)
Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932 (2021) (27)
Section E6.1–6.4 of the ACMG technical standards and guidelines: chromosome studies of neoplastic blood and bone marrow–acquired chromosomal abnormalities (2016) (27)
Infant leukemia and parental infertility or its treatment: a Children's Oncology Group report. (2010) (27)
MLL gene rearrangements in infant leukemia vary with age at diagnosis and selected demographic factors: A Children's Oncology Group (COG) study (2012) (27)
FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631 (2021) (27)
The Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 (P) in treatment-naive (TN) chronic lymphocytic leukemia (CLL) patients (pts): Interim results of a phase Ib/II study. (2012) (27)
Identification of multiple chromosome 12 abnormalities in human testicular germ cell tumors by two‐color fluorescence in situ hybridization (FISH) (1995) (26)
Detection of monosomy 7 in bone marrow by fluorescence in situ hybridization. A study of Fanconi anemia patients and review of the literature. (1999) (26)
Minimally differentiated acute myeloid leukemia (FAB AML-M0) is associated with an adverse outcome in children: a report from the Children's Oncology Group, studies CCG-2891 and CCG-2961. (2007) (25)
Interim Analysis of EFC6663, a Multicenter Phase 2 Study of Alvocidib (flavopiridol), Demonstrates Clinical Responses Among Patients with Fludarabine Refractory CLL (2010) (24)
Characterization of the role of Fhit in suppression of DNA damage. (2013) (23)
Outcome of pediatric patients with acute myeloid leukemia (AML) and −5/5q− abnormalities from five pediatric AML treatment protocols: A report from the Children's Oncology Group (2013) (23)
Impact of Targeted Therapy on Outcome of Chronic Lymphocytic Leukemia Patients with Relapsed Del(17p13.1) Karyotype at a Single Center (2014) (23)
Acute Lymphoblastic Leukemia with Hypereosinophilia: Report of a Case with 5q Deletion and Review of the Literature (2003) (23)
Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131. (2020) (23)
Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium. (2010) (22)
CA180-372: An International Collaborative Phase 2 Trial of Dasatinib and Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) (2017) (22)
Loss of heterozygosity in childhood de novo acute myelogenous leukemia. (2001) (22)
Extended Data Figure 5 (2014) (22)
Prognostic significance of cytogenetic abnormalities of chromosome arm 12p in childhood acute lymphoblastic leukemia (2000) (22)
Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202 (2018) (22)
Mild "duplication 6q syndrome": a case with partial trisomy (6)(q23.3q25.3). (1997) (22)
Cytogenetics and outcome of infants with acute lymphoblastic leukemia and absence of MLL rearrangements (2013) (22)
Efficient identification of marker chromosomes in 27 patients by stepwise hybridization with alpha-satellite DNA probes (1993) (22)
A case with mosaic di-, tetra-, and octacentric ring Y chromosomes. (1997) (22)
Exposure to Medical Test Irradiation and Acute Leukemia Among Children With Down Syndrome: A Report From the Children's Oncology Group (2006) (22)
Mixed‐phenotype acute leukemia: A cohort and consensus research strategy from the Children’s Oncology Group Acute Leukemia of Ambiguous Lineage Task Force (2020) (21)
Independent evaluation of ibrutinib efficacy 3 years post-initiation of monotherapy in patients with chronic lymphocytic leukemia/small lymphocytic leukemia including deletion 17p disease. (2014) (21)
Fluorescence in situ hybridization on nuclei from paraffin-embedded tissue in low stage pure embryonal carcinoma of the testis. (1998) (20)
Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG (2018) (20)
Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia (2018) (20)
Association of disease progression on ibrutinib therapy with the acquisition of resistance mutations: A single-center experience of 267 patients. (2014) (20)
AP-1 elements and TCL1 protein regulate expression of the gene encoding protein tyrosine phosphatase PTPROt in leukemia. (2011) (20)
Prevalence and prognostic implications of WT 1 mutations in pediatric acute myeloid leukemia ( AML ) : a report from the Children ’ s Oncology Group * (2010) (19)
Cytogenetic and molecular analysis of a ring (21) in a patient with partial trisomy 21 and megakaryocytic leukemia. (1994) (19)
Primary hepatic B-cell lymphoma in a child. (1993) (19)
Telomere length and telomerase reverse transcriptase gene copy number in patients with papillary thyroid carcinoma. (2011) (19)
State of the Art and Future Needs in Cytogenetic/Molecular Genetics/Arrays in childhood lymphoma: Summary report of workshop at the First International Symposium on childhood and adolescent non‐Hodgkin lymphoma, April 9, 2003, New York City, NY (2005) (19)
Bicolor fluorescence in situ hybridization on nuclei from formalin-fixed, paraffin-embedded testicular germ cell tumors: comparison with standard metaphase analysis. (1997) (18)
An apparently acentric marker chromosome originating from 9p with a functional centromere without detectable alpha and beta satellite sequences. (1997) (18)
Complex karyotype is associated with aggressive disease and shortened progression-free survival in patients with newly diagnosed mantle cell lymphoma. (2015) (18)
Dexamethasone (DEX) versus prednisone (PRED) during induction for children with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children's Oncology Group Study AALL0232. (2011) (17)
Congenital Abnormalities and Acute Leukemia among Children with Down Syndrome: A Children's Oncology Group Study (2008) (17)
Outcome of Children with Standard‐Risk T‐Lineage Acute Lymphoblastic Leukemia—Comparison among Different Treatment Strategies (2016) (17)
Ethnic Variation of TET2 SNP rs2454206 and Association with Clinical Outcome in Childhood AML: A Report from the Children’s Oncology Group (2015) (17)
Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children’s Oncology Group Study AALL0232 (2021) (17)
Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). (2018) (17)
A Phase I/II Study of Etanercept and Rituximab in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (2009) (17)
Pediatric acute lymphoblastic leukemia with a t(8;14)(q11.2;q32): B-cell disease with a high proportion of Down syndrome: a Children's Oncology Group study. (2012) (17)
Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia. (2006) (16)
Flavopiridol (Alvocidib) Induces Durable Responses in Relapsed Chronic Lymphocytic Leukemia (CLL) Patients with High-Risk Cytogenetic Abnormalities (2008) (16)
Outstanding Outcome for Children with Standard Risk-Low (SR-Low) Acute Lymphoblastic Leukemia (ALL) and No Benefit to Intensified Peg-Asparaginase (PEG-ASNase) Therapy: Results of Children’s Oncology Group (COG) Study AALL0331 (2014) (16)
Enasidenib Is Highly Active in Previously Untreated IDH2 Mutant AML: Early Results from the Beat AML Master Trial (2018) (16)
Escalating Dose Intravenous Methotrexate without Leucovorin Rescue during Interim Maintenance Is Superior to Oral Methotrexate for Children with Standard Risk Acute Lymphoblastic Leukemia (SR-ALL): Children’s Oncology Group Study 1991 (2008) (16)
Interphase chromosome painting of paraffin-embedded tissue in the differential diagnosis of possible germ cell tumors. (1994) (15)
Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease (2010) (15)
Up to 7 Years of Follow-up of Single-Agent Ibrutinib in the Phase 1b/2 PCYC-1102 Trial of First Line and Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (2018) (15)
Characterization of gains, losses, and regional amplification in testicular germ cell tumor cell lines by comparative genomic hybridization. (2004) (15)
Two Down syndrome patients with an acquired translocation, t(8;14)(q11;q32), in early B-lineage acute lymphoblastic leukemia. (1993) (15)
Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study (2012) (15)
Spontaneous remission in myelodysplastic syndrome. A case report. (1990) (14)
Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children's Oncology Group. (2019) (14)
Treatment with Fludarabine and Rituximab Produces Extended Overall Survival (OS) and Progression-Free Survival (PFS) in Chronic Lymphocytic Leukemia (CLL) without Increased Risk of Second Malignancy: Long-Term Follow up of CALGB Study 9712. (2009) (14)
Identification of a Recurrent LMO7-BRAF Fusion in Papillary Thyroid Carcinoma. (2018) (14)
Cytogenetic analyses of 85 testicular germ cell tumors: comparison of postchemotherapy and untreated tumors. (1999) (14)
Vitamin supplement use among children with Down's syndrome and risk of leukaemia: a Children's Oncology Group (COG) study. (2008) (14)
Prevalence and Prognostic Implications of WT1 Mutations in Pediatric AML Â: Report from Children’s Oncology Group (2008) (13)
Capizzi-Style Methotrexate with Pegasparagase (C-MTX) Is Superior to High-Dose Methotrexate (HDMTX) in T-Lineage Acute Lymphoblastic Leukemia (T-ALL): Results from Children's Oncology Group (COG) AALL0434 (2015) (13)
A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485 (2017) (13)
Lumiliximab in combination with FCR for the treatment of relapsed chronic lymphocytic leukemia (CLL): results from a phase I/II multicenter study (2008) (13)
The impact of increasing karyotypic complexity and evolution on survival in CLL patients treated with ibrutinib. (2021) (13)
Initial Report of the Beat AML Umbrella Study for Previously Untreated AML: Evidence of Feasibility and Early Success in Molecularly Driven Phase 1 and 2 Studies (2018) (12)
A BCR-ABL1-Like Gene Expression Profile Confers a Poor Prognosis In Patients with High-Risk Acute Lymphoblastic Leukemia (HR-ALL): A Report From Children's Oncology Group (COG) AALL0232 (2011) (12)
Cytogenetic patterns following bone marrow transplantation for chronic granulocytic leukemia. (1988) (12)
Therapy-related pro-B cell acute lymphoblastic leukemia: report of two patients with MLL amplification. (2011) (12)
Maternal vitamin and iron supplementation and risk of infant leukaemia: a report from the Children's Oncology Group (2010) (12)
Cytogenetic and early-response characteristics of adolescents and young adults with acute lymphoblastic leukemia (ALL): A Children's Oncology Group (COG) study. (2010) (11)
Use of Lymphoid Progenitor Cell Assays for a More Detailed Analysis of the Cytogenetic Changes Occurring During Clonal Evolution in Acute Lymphoblastic Leukemia. (1990) (11)
Phase I study of the CDK inhibitor dinaciclib (SCH 727965) in patients (pts) with relapsed/refractory CLL. (2011) (11)
Integrated Genomic and Mutational Profiling Of Adolescent and Young Adult ALL Identifies a High Frequency Of BCR-ABL1-Like ALL with Very Poor Outcome (2013) (11)
A phase 1b/2 study evaluating activity and tolerability of the BTK inhibitor ibrutinib in combination with ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. (2014) (11)
A Novel Celecoxib Derivative , OSU 03012 , Induces Cytotoxicity in Primary CLL Cells and Transformed B-cell Lymphoma via a Caspase and Bcl-2 Independent Mechanism (2004) (11)
the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL (2016) (11)
Long-Term Results of Alliance A041202 Show Continued Advantage of Ibrutinib-Based Regimens Compared with Bendamustine Plus Rituximab (BR) Chemoimmunotherapy (2021) (11)
Masked Hypodiploidy: Hypodiploid Acute Lymphoblastic Leukemia (ALL) in Children Mimicking Hyperdiploid ALL: A Report From the Children's Oncology Group (COG) AALL03B1 Study. (2009) (10)
The phosphatidylinositol 3-kinase-δ Inhibitor CAL-101 demonstrates promising pre-clinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals (2010) (10)
Outcomes of dasatinib plus intensive chemotherapy or stem cell transplant (SCT) for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) on Children’s Oncology Group AALL0622. (2015) (10)
Phase 1 Trial of Flavopiridol and Lenalidomide In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL) (2010) (10)
Cytogenetic abnormalities and molecular markers of acute lymphoblastic leukemia. (1990) (9)
Complex secondary chromosome abnormalities in advanced stage anaplastic large cell lymphoma of children and adolescents: a report from CCG-E08. (2006) (9)
A Pilot Study of Intensified PEG-Asparaginase in High-risk Acute Lymphoblastic Leukemia: Children’s Oncology Group Study AALL08P1 (2016) (9)
Biology-Driven Classification of Childhood Acute Lymphoblastic Leukemia: A Combined Analysis of Prognostic Markers from the Pediatric Oncology Group (POG) and Children’s Cancer Group (CCG). (2004) (9)
Periconceptional vitamin useand leukemia risk in children with Down syndrome: a Children's Oncology Group study. (2005) (9)
Continuous Dose Dasatinib Is Safe and Feasible in Combination with Intensive Chemotherapy in Pediatric Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Children's Oncology Group (COG) Trial AALL0622 (2012) (9)
Activity of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed, genetically high risk chronic lymphocytic leukemia (CLL) (2008) (8)
Favorable Trisomies and ETV6-RUNX1 Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331 (2021) (8)
TET2 SNP rs2454206 (I1762V) Correlates with Improved Survival In Pediatric Acute Myelogenous Leukemia, a Report From the Children's Oncology Group (2010) (8)
Jumping translocations, a novel finding in chronic lymphocytic leukaemia (2015) (8)
Genomic Characterization and Experimental Modeling Of BCR-ABL1 -Like Acute Lymphoblastic Leukemia (2013) (8)
The natural history of chronic myelogenous leukemia in a renal transplant recipient. (1996) (8)
Specific MLL Partner Genes in Infant Acute Lymphoblastic Leukemia (ALL) Associated with Outcome Are Linked to Age and White Blood Cell Count (WBC) at Diagnosis: A Report On the Children's Oncology Group (COG) P9407 Trial. (2009) (8)
Association of abnormal cytogenetics at date of morphologic complete remission (CR) with overall (OS), disease-free survival (DFS) and higher relapse rate in acute myeloid leukemia (AML): Results from Cancer and Leukemia Group B (CALGB) 8461 (2004) (8)
Early postinduction intensiﬁcation therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children’s Oncology Group (2008) (7)
Dinaciclib (SCH 727965) and Ofatumumab for the Treatment of Relapsed and Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): Results of a Phase 1b/2 Study (2014) (7)
Triple Intrathecal Therapy (Methotrexate/Hydrocortisone/Cytarabine) Does Not Improve Disease-Free Survival Versus Intrathecal Methotrexate Alone in Children with High Risk B-Lymphoblastic Leukemia: Results of Children's Oncology Group Study AALL1131 (2018) (7)
A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab in Relapsed CLL/SLL: Clinical Activity in the Absence of Del(17p13) Genomic Abnormalities. (2006) (7)
Flavopiridol Is Active in Genetically High-Risk, Relapsed Chronic Lymphocytic Leukemia (CLL): Analysis of 56 Patients by Cytogenetic Abnormality. (2006) (7)
Hematopoietic stem cell transplant (HSCT) versus intensive chemotherapy in infant acute lymphoblastic leukemia (ALL) (2007) (7)
Cytogenetic findings in siblings with a myelodysplastic syndrome. (1987) (7)
CytoGPS: a web-enabled karyotype analysis tool for cytogenetics (2019) (7)
Impact of corticosteroid pretreatment in pediatric patients with newly diagnosed B-lymphoblastic leukemia: a report from the Children’s Oncology Group (2019) (7)
Precision Medicine Treatment in Older AML: Results of Beat AML Master Trial (2019) (7)
Excellent Outcomes with Reduced Frequency of Vincristine and Dexamethasone Pulses in Children with National Cancer Institute (NCI) Standard-Risk B Acute Lymphoblastic Leukemia (SR B-ALL): A Report from Children's Oncology Group (COG) Study AALL0932 (2019) (7)
Patients with chronic lymphocytic leukemia with high-risk genomic features have inferior outcome on successive Cancer and Leukemia Group B trials with alemtuzumab consolidation: subgroup analysis from CALGB 19901 and CALGB 10101 (2013) (7)
Safety and biological activity of the FLT3 inhibitor lestaurtinib in infant MLL-rearranged (MLL-r) ALL: Children's Oncology Group protocol AALL0631. (2012) (7)
Immune-Related Conditions and Acute Leukemia in Children with Down Syndrome: A Children's Oncology Group Report (2014) (7)
Characterization of seven DA/DAPI-positive bisatellited marker chromosomes by in situ hybridization (1991) (7)
Outcomes of Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Based on Blast Genotype at Diagnosis: A Report from the Children's Oncology Group (2016) (6)
Intensification of Oral Methotrexate Is Not Superior to Standard Methotrexate Dosing during Maintenance in Children with National Cancer Institute (NCI) Standard-Risk B Acute Lymphoblastic Leukemia (SR B-ALL): A Report from Children's Oncology Group (COG) Study AALL0932 (2017) (6)
Improved Post-Induction Chemotherapy Does Not Abrogate Prognostic Significance of Minimal Residual Disease (MRD) for Children and Young Adults with High Risk Acute Lymphoblastic Leukemia (ALL). A Report From Children's Oncology Group (COG) Study AALL0232 (2011) (6)
Cytogenetic analysis of hematologic malignant diseases (2017) (6)
BIRC 5 ( Survivin ) Splice Variant Expression Correlates With Refractory Disease and Poor Outcome in Pediatric Acute Myeloid Leukemia : A Report From the Children ’ s Oncology Group (2014) (6)
Characterization of multiple 12p rearrangements in testicular germ cell tumor cell line 833K and its subclone 64CP by chromosome microdissection. (1998) (6)
CCG 1953: Acute Lymphoblastic Leukemia in Infants: Analysis of Prognostic Factors: A Report from the Children’s Oncology Group. (2005) (6)
Prognostic Utility of the European LeukemiaNet (ELN) Genetic-Risk Classification in Adults with De Novo Acute Myeloid Leukemia (AML): A Study of 1,550 Patients (Pts) (2011) (6)
Comparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexate plus asparaginase (C-MTX/ASNase) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): A report from the Children's Oncology Group Study AALL0232. (2011) (6)
Genome-Wide Analysis of Genetic Alterations In Hypodiploid Acute Lymphoblastic Leukemia Identifies a High Frequency of Mutations Targeting the IKAROS Gene Family and Ras Signaling (2010) (6)
Two Distinct Subsets of dic(9;12)(p12;p11.2) among Children with B-Cell Precursor Acute Lymphoblastic Leukemia (ALL): PAX5-ETV6 and ETV6-RUNX1 Rearrangements: A Report from the Children’s Oncology Group. (2007) (6)
Text Mining and Data Modeling of Karyotypes to aid in Drug Repurposing Efforts (2016) (6)
Phase 1b Dose Escalation Study of BI 836858 and Azacitidine in Previously Untreated AML: Results from Beat AML S2 (2018) (5)
Prognostic significance of translocations in the presence of mutated IGHV and of cytogenetic complexity at diagnosis of chronic lymphocytic leukemia (2020) (5)
mdm-2 oncoprotein expression associated with deletion of the long arm of chromosome 12 in a case of mantle cell lymphoma with blastoid transformation [corrected]. (1996) (5)
The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia (2019) (5)
Sex‐based disparities in outcome in pediatric acute lymphoblastic leukemia: a Children’s Oncology Group report (2022) (5)
Congenital monoblastic leukemia cutis. A case report with chromosomal abnormality: del (10p). (1986) (5)
Assessment of end induction minimal residual disease (MRD) in childhood B precursor acute lymphoblastic leukemia (ALL) to eliminate the need for day 14 marrow examination: A Children’s Oncology Group study. (2013) (5)
Acute Lymphoblastic Leukemia in Children with Down Syndrome: A Report From the Ponte Di Legno Study Group (2011) (5)
Clinical Activity of Flavopiridol in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) with High-Risk Cytogenetic Abnormalities: Updated Data on 89 Patients (Pts). (2007) (5)
Distinct in vivo engraftment and growth patterns of t(1;19)+/E2A-PBX1+ and t(9;22)+/BCR-ABL+ human leukemia cells in SCID mice. (1998) (5)
Polypoid endobronchial Hodgkin lymphoma with an initial response to photodynamic therapy. (2003) (5)
Outstanding outcomes in infants with KMT2Agermline acute lymphoblastic leukemia treated with chemotherapy alone: results of the Children’s Oncology Group AALL0631 trial (2022) (5)
Cytogenetics of leukemia. (1998) (4)
Klinefelter syndrome and 47,XYY syndrome in children with B cell acute lymphoblastic leukaemia (2017) (4)
Promyelocytic Leukemia with No Retinoic Acid Receptor Alpha Abnormality but with RUNX1T1 Insertion to Chromosome 7q: A Classification and Management Dilemma (2015) (4)
Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL) (2019) (4)
Expression of fragile sites in childhood acute lymphoblastic leukemia patients and normal controls (1988) (4)
Select High Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy with Fludarabine and Rituximab in Chronic Lymphocytic Leukemia (CLL): Preliminary Justification for Risk-Adapted Therapy. (2004) (4)
Imatinib in Children with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CP CML): AAML0123 COG Study. (2006) (4)
Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR). (2007) (4)
Genetic and Response-Based Risk Classification Identifies a Subgroup of NCI High Risk Childhood B-Lymphoblastic Leukemia (HR B-ALL) with Outstanding Outcomes: A Report from the Children's Oncology Group (COG) (2015) (4)
Outcomes of Patients with CRLF2-Overexpressing Acute Lymphoblastic Leukemia without Down Syndrome: A Report from the Children's Oncology Group (2020) (4)
9p Rearrangements in ALL (2011) (4)
Multifocal primary neuroblastoma (2005) (4)
Extended Data Table 1 (2014) (4)
Response, Progression-Free Survival, and Overall Survival of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Flavopiridol: Impact of Poor Risk Cytogenetic Abnormalities (2010) (4)
iAMP21 Is Associated with Inferior Outcomes in Children with Acute Lymphoblastic Leukemia (ALL) on Contemporary Children's Oncology Group (COG) Studies (2011) (4)
Activity of Combined Flavopiridol and Lenalidomide in Patients with Cytogenetically High Risk Chronic Lymphocytic Leukemia (CLL): Updated Results of a Phase I Trial, (2011) (4)
Efficacy of ALL Therapy for WHO2016-Defined Mixed Phenotype Acute Leukemia: A Report from the Children's Oncology Group (2017) (3)
The WT1 synonymous SNP rs16754 Is Associated with Higher mRNA Expression and Predicts Significantly Improved Outcome In Favorable-Risk Pediatric AML: a Report From the Children's Oncology Group (2010) (3)
FLT3 Inhibitor Correlative Laboratory Assays Impact Outcomes in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia (ALL) Patients Treated with Lestaurtinib: AALL0631, a Children's Oncology Group Study (2019) (3)
Abstracts From the 48th Congress of the International Society of Paediatric Oncology (SIOP) Dublin, Ireland October 19-22, 2016. (2016) (3)
Prevalence of Inherited Cancer Predisposition Mutations in a Cohort of Older AML Patients Enrolled on the Beat AML Master Trial (2019) (3)
Racial and ethnic disparities in childhood and young adult acute lymphocytic leukaemia: secondary analyses of eight Children's Oncology Group cohort trials. (2023) (3)
Novel Chromosome 5 Inversion Associated With PDGFRB Rearrangement in Hypereosinophilic Syndrome. (2016) (3)
Outcomes with reduced intensity therapy in a low-risk subset of children with National Cancer Institute (NCI) standard-risk (SR) B-lymphoblastic leukemia (B-ALL): A report from Children’s Oncology Group (COG) AALL0932. (2020) (3)
Enhanced Risk Stratification of 21,178 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia (ALL) Incorporating White Blood Count (WBC), Age, and Minimal Residual Disease (MRD) at Day 8 and 29 As Continuous Variables: A Children's Oncology Group (COG) Report (2020) (3)
Mixed Lineage Leukemia Rearrangements (MLL-R) Are Determinants of High Risk Disease in Homeobox A (HOXA)-deregulated T-Lineage Acute Lymphoblastic Leukemia: A Children's Oncology Group Study (2015) (3)
A Novel Regimen for Acute Myeloid Leukemia with MLL Partial Tandem Duplication: Results of a Phase 1 Study NCI 8485 (2016) (3)
Secondary Chromosomal Abnormalities Appear to Be Less Prognostic for Children with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Treated with Intensified Imatinib and Chemotherapy: Results of the Children's Oncology Group (COG) Study AALL0031. (2009) (3)
The impact of initial cerebrospinal fluid (CSF) findings on outcome among patients with NCI standard (SR) and high-risk (HR) B-lymphoblastic leukemia (ALL): A report from the Children’s Oncology Group (COG) Studies AALL0331 and AALL0232. (2014) (3)
Central Review of Cytogenetics Is Essential for Cooperative Group Clinical and Correlative Studies of Acute Leukemia: The Cancer and Leukemia Group B (CALGB) 8461 Experience. (2004) (3)
Children with Down Syndrome (DS) and NCI Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Have a Superior Five-Year Event-Free Survival (EFS) When Treated with Escalating Intravenous Methotrexate on the Children's Cancer Group (CCG) Study 1991 (2010) (2)
A Phase 2 Study of Lenalidomide to Repair Immune Synapse Response and Humoral Immunity in Early-Stage, Asymptomatic Chronic Llmphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) with High-Risk Genomic Features (2016) (2)
Identification of novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia (2009) (2)
Minimal Residual Disease Assessment of Remission after Induction Therapy Is Superior to Morphologic Assessment for Risk Stratification in Childhood Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group (COG) (2016) (2)
Complex Karyotype (CK) Is Associated with a Shortened Progression-Free Survival (PFS) in Patients (pts) with Newly Diagnosed Mantle Cell Lymphoma (MCL). (2012) (2)
Prognostic impact of minimal residual disease at the end of consolidation in NCI standard‐risk B‐lymphoblastic leukemia: A report from the Children's Oncology Group (2021) (2)
A Pilot Study of Azacitidine As Epigenetic Priming for Chemotherapy in Infants Less Than 1 Year of Age with KMT2A-Rearranged Acute Lymphoblastic Leukemia (ALL); Results from the Children's Oncology Group (COG) Trial AALL15P1 (2022) (2)
Outcomes of Patients with Down Syndrome and CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG) (2020) (2)
30 Common chromosomal findings in ovarian and endometrial tumors (1987) (2)
Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients (2013) (2)
report from the Children's Oncology Group a children and adolescents with high-risk acute lymphoblastic leukemia: Early postinduction intensification therapy improves survival for (2011) (2)
Abstract 4729: Frequency of actionable gene fusions in patients with Philadelphia chromosome-like (Ph-like) B-acute lymphoblastic leukemia (ALL): A retrospective study from the Children's Oncology Group (COG) (2015) (2)
CEBPA Mutations Predict Favorable Prognosis in Pediatric AML (2008) (2)
Inferring clonal heterogeneity in cancer using SNP arrays and whole genome sequencing (2019) (2)
Outcomes in children with Down syndrome (DS) and B-lymphoblastic leukemia (B-ALL): A Children’s Oncology Group (COG) report. (2020) (2)
Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq (2021) (2)
Flow cytometric vs morphologic assessment of remission in childhood acute lymphoblastic leukemia: A report from the Children's Oncology Group (COG). (2017) (2)
PI3K/AKT/mTOR Signaling Is a Significant Druggable Pathway In Infant Acute Lymphoblastic Leukemia (ALL) (2013) (2)
Culture and Harvest of CpG-Stimulated Peripheral Blood or Bone Marrow in Chronic Lymphocytic Leukemia. (2018) (2)
Chromosomes in lymphomas and solid tumors. (1998) (2)
Novel Clonal t(2;4) (q23;p14) Secondary Cytogenetic Abnormality in a Primary Myxoid Liposarcoma (2015) (2)
Rare t(X;14)(q28;q32) translocation reveals link between MTCP1 and chronic lymphocytic leukemia (2021) (2)
A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL) (2021) (2)
Novel t(1;2)(p36.1;q23) and t(7;19)(q32;q13.3) chromosomal translocations in ischemic fasciitis: expanding the spectrum of pseudosarcomatous lesions with clonal pathogenetic link (2018) (2)
Prevalence and Clinical Implications of N-RAS Mutations in Childhood AML – A Report From the Children's Oncology Group. (2009) (2)
A genetic risk-stratified, randomized phase 2 intergroup study of fludarabine/antibody combinations in symptomatic, untreated chronic lymphocytic leukemia (CLL): Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance). (2017) (2)
Clinical Impact of Additional Cytogenetic Aberrations and Complex Karyotype In Pediatric 11q23/ MLL -Rearranged AML: Results from an International Retrospective Study (2010) (2)
Amplification of AML1 Does Not Impact Early Outcome of Children with Acute Lymphoblastic Leukemia (ALL) Treated with Risk-Directed Chemotherapy: A Report From the Children's Oncology Group (COG). (2009) (2)
Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders Is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial (2020) (2)
Minimal residual disease at end of induction and consolidation remain important prognostic indicators for newly diagnosed children and young adults with very high-risk (VHR) B-lymphoblastic leukemia (B-ALL): Children’s Oncology Group AALL1131. (2021) (2)
Philadelphia Chromosome Negative (Ph-) Very High Risk (VHR) Acute Lymphoblastic Leukemia (ALL) in Children and Adolescents: The Impact of Intensified Chemotherapy on Early Event Free Survival (EFS) in Children’s Oncology Group (COG) Study AALL0031. (2008) (1)
A Phase II study of the efficacy and tolerability of Lapatinib in patients with advanced hepatocellular carcinomas. (2008) (1)
Sex-Based Disparities in Outcome in Childhood Acute Lymphoblastic Leukemia (ALL): A Children's Oncology Group (COG) Report (2020) (1)
Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children’s Oncology Group trial AALL0631 (2021) (1)
24. Abbott Vysis IntelliFISH Hybridization Buffer evaluation on hematological specimens (2018) (1)
RUNX1 Mutations in Pediatric AML: A Report From the Children's Oncology Group. (2009) (1)
Final Results of a Phase II Study of Fc Engineered, CD19 Antibody Tafasitamab in Combination with Lenalidomide or Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL) (2020) (1)
Outcomes in Children and Adolescents with a Markedly Elevated White Blood Cell Count (>200,000) at Diagnosis of High Risk Acute Lymphoblastic Leukemia (ALL): A Report from the Children’s Oncology Group. (2006) (1)
Genomic- and Transcriptomic Profiling Of Acute Lymphoblastic Leukemia With Dicentric Chromosomes (2013) (1)
CytoGPS: A large-scale karyotype analysis of CML data. (2020) (1)
Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib (2020) (1)
The association of aneuploidy and unexplained elevated maternal serum alpha-fetoprotein. (1998) (1)
del(17p13.1) in Chronic Lymphocytic Leukemia Confers Poor Prognosis Even at Low Percentage Involvement and Increases Proportionately with Increase in Clonal Involvement. (2007) (1)
Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at Enrolling Institutions Compared to Central Laboratory Results in the Beat AML Master Trial (2019) (1)
Increasing Genetic Complexity Predicts for Inferior Outcomes Following Reduced-Intensity Conditioning Allogeneic Transplant for Chronic Lymphocytic Leukemia (2011) (1)
A Phase II Study of the TNF-α Inhibitor Etanercept and Thrice Weekly Rituximab: Evidence of Clinical Activity in the Absence of del(17p13.1) Genomic Abnormalities. (2004) (1)
A Next-Generation Sequencing-Based Karyotyping Algorithm Reveals the Genomic Structure of Acute Myeloid Leukemia (2018) (1)
Cytogenetic findings of a child with transcobalamin II deficiency. (1993) (1)
Minimal Toxicity of Imatinib Mesylate in Combination with Intensive Chemotherapy for Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) in Children: A Report of the Children’s Oncology Group (COG) AALL0031 Protocol for Very High Risk ALL. (2006) (1)
WT1 snp rs16754 Genotype Predicts Treatment Related Mortality (TRM) in African-American and Asian Pediatric AML Patients: A Report From the Children's Oncology Group (2012) (1)
Whole Exome Sequencing of Pediatric Acute Lymphoblastic Leukemia Patients Identify Mutations in 11 Pathways: A Report from the Children's Oncology Group (2016) (1)
Abstract 222: Genome-wide association study of acute lymphoblastic leukemia in children with Down syndrome (2018) (1)
Cytogenetics in Children, Adolescents and Young Adults with ALL and AML (2012) (1)
Cytogenetic Subgroups Drive Risk Stratification and Response to Chemotherapy and Blinatumomab in Children and Young Adults with Relapsed B-ALL: A Children's Oncology Group Study (2020) (1)
Gene expression proﬁles predictive of outcome and age in infant acute lymphoblastic leukemia: a Children’s Oncology Group study (2012) (1)
VpreB surrogate light chain expression in B-lineage ALL: a report from the Children’s Oncology Group (2021) (1)
Genomic Analysis of Cellular Hierarchy in Acute Myeloid Leukemia Using Ultrasensitive LC-FACS-Seq (2019) (1)
Central Nervous System Status is Prognostic in T-Cell Acute Lymphoblastic Leukemia: A Children's Oncology Group Report. (2023) (1)
Abstract 4870: Integrated genomic analysis of hypodiploid acute lymphoblastic leukemia (2012) (1)
In Pediatric Mature B-Cell Non Hodgkin Lymphoma (NHL), Complex Karyotype or del(13q) Are Linked Prognostic Factors in Burkitt Lymphoma (BL) While 8q24/c-myc Rearrangement Is Associated with a Strong Adverse Effect in Diffuse Large B-Cell Lymphoma (DLBCL). (2005) (1)
Barriers to Proceeding to Reduced-Intensity Allogeneic Stem Cell Transplant in Chronic Lymphocytic Leukemia (2013) (1)
Gene Expression Profiling in Down Syndrome Acute Lymphoblastic Leukemia Identifies Distinct Profiles Associated with CRLF2 Expression Status. (2009) (1)
Presence of a Translocation Is Associated with Short Time to Treatment from Diagnosis in IGHV Mutated Chronic Lymphocytic Leukemia (CLL) Patients (2016) (1)
Genome-Wide DNA Methylation Analysis Reveals Biological and Clinical Insights In Relapsed Childhood Acute Lymphoblastic Leukemia: A Report From The COG ALL Target Project (2013) (1)
Improved Diagnosis of Intrachromosomal Amplification of Chromosome 21 (iAMP21) By Copy Number Profiling (2016) (1)
Children with NCI Standard Risk Acute Lymphoblastic Leukemia (ALL) and TEL-AML1 or Favorable Chromosome Trisomies Are Almost Certain to Be Cured with Graduated Intensity Therapy: Results of the CCG - 1991 Study. (2009) (1)
Infant Acute Lymphoblastic Leukemias Are Pan-Sensitive to Obatoclax Across molecular/Cytogenetic Subtypes, Especially MLL-ENL, and gene Expression Profiles Determine Obatoclax IC50: A Report on the Children's Oncology Group (COG) P9407 Trial (2010) (1)
Maternal Hemoglobin Concentration during Pregnancy and Risk of Infant Leukemia. (2005) (1)
Spontaneous expression of fra(10)(q25) in bone marrow from a patient with agranulocytosis. (1988) (1)
Children ' s Cancer Group lymphoblastic leukemia : a combined analysis of prognostic markers Risk-and response-based classification of childhood B-precursor acute (2007) (1)
AF10 Fusion Transcripts Are Identified By HOXA9/10 and MEIS1 Overexpression In T-ALL: A Report From Children’s Oncology Group AALL0434 (2013) (1)
NPM1 mutations Using Deep Amplicon Sequencing and Broad Next Generation Sequencing at the Time of Complete Remission Is Informative to Predicting Risk of Relapse Following Intensive Chemotherapy (2019) (1)
Attainment of Minimal Residual Disease Negative State Is Crucial for Successful Outcome of Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Advanced Chronic Lymphocytic Leukemia (CLL). (2008) (1)
Prevalence and Prognostic Implications of CEBPα Mutations in Pediatric AML. (2007) (1)
Alemtuzumab Consolidation Does Not Improve Outcome for CLL Patients with High Risk Genomic Features on Successive CALGB Trials. (2011) (1)
Durable Responses Including Complete Responses in CLL Following Long Term Treatment With Single-agent Ibrutinib 420 mg (2015) (1)
Acute Lymphoblastic Leukemia (ALL) with t(8;14)(q11.2;q32): B-Lineage Disease with High Proportion of Down Syndrome. A Children’s Oncology Group (COG) Study. (2008) (1)
independent mechanism - Bcl-2 CLL cells and transformed B-cell lymphoma cell line via a caspase- and A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary (2013) (0)
Racial and Ethnic Differences in Survival of Children with Acute Lymphoblastic Leukemia Running title: Childhood acute lymphoblastic leukemia outcome by race Scientific Section Heading: Clinical Observation, Intervention and Therapeutic Trials (2002) (0)
17. CytoGPS: A novel bioinformatics approach for high-throughput karyotype analysis (2018) (0)
Ivosidenib (IVO) in Combination with Azacitidine (AZA) in Newly Diagnosed (ND) Older Patients with IDH1 R132-Mutated Acute Myeloid Leukemia (AML) Induces High Response Rates: A Phase 2 Sub-Study of the Beat AML Master Trial (2021) (0)
Novel Clonal der(9)t(5;9)(q31;q34) Cytogenetic Translocation in a Giant Cell Tumor of Bone (2015) (0)
A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML) (2022) (0)
TET2 Mutations Are Associated with Poor Outcome in Pediatric AML: A Report From the Children's Oncology Group (2011) (0)
Genomic landscape of Down syndrome-associated acute lymphoblastic leukemia. (2023) (0)
cooperative trials for de novo AML patients with core binding factor AML enrolled on serial pediatric mutations in pediatric KIT Prevalence and prognostic significance of (2011) (0)
Gene Expression Profiling Reveals Genes Predictive of Outcome In Infant Acute Lymphoblastic Leukemia (ALL) and Distinctive Age-Related Gene Expression Profiles ( 90 Days): A Children's Oncology Group Study (2010) (0)
Leukemia-initiating HSCs in chronic lymphocytic leukemia reveal clonal leukemogenesis and differential drug sensitivity. (2022) (0)
The genetic basis and cell of origin of mixed phenotype acute leukaemia (2018) (0)
Update o n L ate R elapse o f G erm C ell T umor: A C linical a nd Molecular A nalysis (2003) (0)
Association of abnormal cytogenetics at date of morphologic complete remission (CR) with overall (OS), disease-free survival (DFS) and higher relapse rate in acute myeloid leukemia (AML): Results from Cancer and Leukemia Group B (CALGB) 8461. (2004) (0)
Complete Response (CR) to Induction Therapy in Patients (pts) with Myc+ and Double Hit Non-Hodgkin's Lymphoma (NHL) Is Associated with Prolonged Progression-Free Survival (PFS). (2012) (0)
Atlas of Genetics and Cytogenetics in Oncology and Haematology (2003) (0)
Prevalence and Prognostic Significance of c-KIT Mutations in Pediatric CBF AML Patients Enrolled on Serial CCG/COG Protocols. (2007) (0)
Karyotype Results From CpG Oligodeoxynucleotide Stimulated Chronic Lymphocytic Leukemia (CLL) Cultures Are Consistent Among Laboratories: a CLL Research Consortium (CRC) Study. (2009) (0)
Interleukin-15 Is a Proto-Oncogene In Acute Large Granular Lymphocyte Leukemia (2010) (0)
high-risk chronic lymphocytic leukemia associated with marked clinical efficacy in refractory, genetically Flavopiridol administered using a pharmacologically derived schedule is (2013) (0)
Resistance to the Novel Translation Inhibitor Silvestrol Is Mediated by Elevated Mcl-1 Expression. (2009) (0)
Novel jumping translocations (JT) associated with genetic instability and aggressive disease in chronic lymphocytic leukemia (CLL). (2011) (0)
Mcl-1 as a Possible Predictor of Progression-Free Survival in Previously Untreated Chronic Lymphocytic Leukemia Patients Treated with Pentostatin, Cyclophosphamide and Rituximab. (2008) (0)
Outcome of Pediatric Patients with Acute Myeloid Leukemia and -5/5q-Abnormalities Enrolled On Five Children's Oncology Group Acute Myeloid Leukemia Treatment Protocols (2012) (0)
cyclophosphamide, and rituximab lymphocytic leukemia patients treated with pentostatin, Mcl-1 expression predicts progression-free survival in chronic (2013) (0)
Leukemic Blasts With The PNH Phenotype: Correlation With Cytogenetics In ALL (2013) (0)
iAMP21 in Childhood ALL: It's not Just a Case for G-Banding and Fluorescence In Situ Hybridization (FISH) Analyses; Array to the Rescue (2017) (0)
FLUORESCENCE IN SITU HYBRIDIZATION ON NUCLEI FROM CARCINOMA OF THE TESTIS PARAFFIN-EMBEDDED TISSUE IN LOW STAGE PURE EMBRYONAL (1998) (0)
Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib (2016) (0)
Age Is the Strongest Determinant of Leukemia Blast Cell Gene Expression in MLL -Rearranged Infant ALL and MLL-AF4 Directs a Distinct Gene Expression Profile Related to CNS Disease. (2008) (0)
Normal FISH CLL Represents a Heterogeneous Subgroup Where Prognosis Can be Refined with IGHV Mutational Status (2021) (0)
Integrated Genomic Analysis of Down Syndrome Acute Lymphoblastic Leukemia Reveals Recurrent Cancer Gene Alterations and Evidence of Frequent Subclonal Driver Events (2016) (0)
The significance of BCL6 abnormalities on fluorescence in situ hybridization (FISH) in chronic lymphocytic leukemia (CLL). (2016) (0)
Plenary paper Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia (2006) (0)
Comparison of Current and Enhanced Risk Stratification of 21,199 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Using Objective Risk Categorization Criteria: A Children's Oncology Group Report (2021) (0)
WWOX-deficiency promotes increased survival by enhancing homology-directed repair (2017) (0)
KMT2A partner genes in infant acute lymphoblastic leukemia have prognostic significance and correlate with age, white blood cell count, sex, and central nervous system involvement: a Children's Oncology Group P9407 trial study. (2023) (0)
Activity and Tolerability of Ibrutinib in Combination With Ofatumumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (2015) (0)
Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932. (2023) (0)
Genetic Susceptibility Loci and Risk of Infant Leukemia by Subtype and MLL status: A Children's Oncology Group Report (2011) (0)
Subject Index Vol. 123, 2010 (2010) (0)
Initial characterization of a human megakaryocytic leukemia cell line, EST-IU. (1986) (0)
A PROSPECTIVE COMPARISON OF INTRAOPERATIVE UROVYSION FISH AND URINARY CYTOLOGY (2009) (0)
Rearrangement of CRLF2 in B-Progenitor and Down Syndrome Associated Acute Lymphoblastic Leukemia. (2009) (0)
Metaphase Cytogenetics in Chronic Lymphocytic Leukemia (2016) (0)
Acute Myeloid Leukemia (AML) with t(6;9)(p23;q34) Defines a Very Poor Risk Leukemia Subgroup with Distinguishing Clinicopathological Features: A United States (US) Cytogenetics Intergroup Study of 62 AML and MDS Cases. (2004) (0)
Cancer Group Childhood Acute Lymphoblastic Leukemia: A Report From the Children's Hypodiploidy With Less Than 45 Chromosomes Confers Adverse Risk in (2011) (0)
The Ratio of Alternate BIRC5 (Survivin) Splice Variants Correlates with Refractory Disease and Poor Outcome in Children with Acute Myeloid Leukemia: A Report From the Children's Oncology Group (2011) (0)
Subject Index Vol. 39, 1985 (1985) (0)
Mutations in the Ras Pathway in Pre-Treatment Chronic Lymphocytic Leukemia Are Associated with VH1-69: Linking B-Cell Receptor Stereotypy to Downstream Signaling Events (2018) (0)
Pre-B cell receptor expression in B-lineage acute lymphoblastic leukemia: A report from the Children’s Oncology Group. (2021) (0)
Entospletinib (ENTO) and Decitabine (DEC) Combination Therapy in Older Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Patients with Mutant TP53 or Complex Karyotype Is Associated with Poor Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial (2021) (0)
protein tyrosine phosphatase PTPROt in leukemia AP-1 elements and TCL1 protein regulate expression of the gene encoding (2012) (0)
Abstract 1721: Resistance to silvestrol is mediated by MDR1/Pgp over-expression in a lymphoblastic leukemia cell line and is reversible by treatment with rapamycin (2011) (0)
TCL1 Expression in Chronic Lymphocytic Leukemia Correlates with the Intensity of 11q Deletions and ZAP-70. (2007) (0)
Extended Data Legend (2014) (0)
Chromosome Fragile Sites Signature and Genome Instability in Human Epithelial cells (2013) (0)
Changing The Treatment Paradigm For Previously Treated Chronic Lymphocytic Leukemia Patients With Del(17p) Karyotype (2013) (0)
Gene Expression Profiling Differentiates Childhood Acute Lymphoblastic Leukemia in Down Syndrome Versus Non-Down Syndrome Patients. (2008) (0)
Triple color FISH detection of 12p amplification in testicular germ-cell tumors using 12p band-specific painting probes (1997) (0)
Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients (2021) (0)
New Insights into Deregulated Gene Expression Pathways in MLL- and AF10-Rearranged T-Lineage Acute Lymphoblastic Leukemia (2016) (0)
Group acute myeloid leukemia (AML): a report from the Children's Oncology Prevalence and prognostic implications of WT1 mutations in pediatric (2013) (0)
Abstract 4755: Genome wide analysis of hypodiploid acute lymphoblastic leukemia identifies a high frequency of mutations targeting the IKAROS gene family and Ras signaling (2011) (0)
Prognostic Importance of Cytogenetic Subgroups in Relapse Risk Stratification in Children and Young Adults with First Relapsed B-ALL: A Children's Oncology Group Study AALL1331 (2022) (0)
9. Enhanced detection of chromosomal abnormalities in Hairy Cell Leukemia by conventional cytogenetics using oligonucleotide stimulation (2021) (0)
Dic(17;18)(p11.2;p11.2) Is a Recurring Abnormality in Chronic Lymphocytic Leukemia Associated with Aggressive Disease. (2009) (0)
Outcome in Adolescent and Young Adult (AYA) Patients Compared to Younger Patients Treated for High-Risk B-Lymphoblastic Leukemia (HR B-ALL): Report from the Children's Oncology Group Study AALL0232 (2019) (0)
Contents Vol. 123, 2010 (2010) (0)
FISH Analysis of CDKN2A/B Deletion in Chronic Lymphocytic Leukemia (2022) (0)
A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2-Mutant AML Patients: 3-Year Follow-up (2022) (0)
Complex Karyotype Predicts Poor Response To Salvage Therapy And Ineligibility For Reduced Intensity Conditioning Transplantation In CLL (2010) (0)
A prospective comparison of UroVysion FISH and urine cytology in bladder cancer detection (2017) (0)
871 Deficiency of the WWOX Fragile Gene Impairs DNA Damage Response (2010) (0)
Validation of CLL FISH Panel Scoring by Members of the Chronic Lymphocytic Leukemia Research Consortium. (2008) (0)
Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial. (2023) (0)
Prognostic Impact of CNS-2 status in T-ALL: A report from the Children’s Oncology Group. (2021) (0)
Expression Profiling for MEIS1 and HOXA9/10 Identifies an Increased Incidence of MLL Rearrangements in T-ALL: A Children's Oncology Group Study. (2012) (0)
Intensification o f T herapy f or C hildren W ith L ower-Risk A cute Lymphoblastic L eukemia: L ong-Term F ollow-Up o f P atients Treated o n C hildren's C ancer G roup T rial 1 881 (2003) (0)
2018 ASPHO ABSTRACTS (2018) (0)
MLL Rearrangement and Age At Diagnosis Are Strongly Associated with High Level Surface FLT3 Expression and Ex Vivo Sensitivity to FLT3 Inhibition: A Prospective Analysis of 54 Consecutive Infants with ALL Enrolled in Children's Oncology Group (COG) Trial AALL0631 (2011) (0)
Combination therapy with etanercept and rituximab in relapsed CLL/SLL (2008) (0)
Chromosomal Fusion Transcript Expression in the MLL-AF 4 Clinical Significance of (1998) (0)
Simultaneous supratentorial anaplastic and infratentorial low grade ependymomas with distinct genetic profiles. (2018) (0)
Paternal military service and risk of leukemia among children with Down syndrome: A children’s oncology group (COG) study (2008) (0)
50. Different cytogenetic culture conditions yield surprising results (2018) (0)
Abstract CT132: Long-term treatment with single-agent ibrutinib 420 mg leads to durable responses including complete responses in CLL (2015) (0)
Abstract 3014: BCL3 over-expression contributes anin vivogrowth advantage in a B-cell lymphoma xenograft model and is a risk factor for ibrutinib relapse in CLL (2017) (0)
Children's Oncology Group for standard-risk acute lymphoblastic leukemia, reported by the methotrexate: results of the Children's Cancer Group (CCG) 1952 study fails to improve event-free survival when compared with intrathecal Intrathecal triple therapy decreases central nervous system relapse but (2013) (0)
Early Response to Therapy Is Significantly Associated with Genetic Subtype of Acute Lymphoblastic Leukemia: A Report from the Children’s Oncology Group. (2007) (0)
international study -rearranged AML patients: results of an MLL novo pediatric 11q23/ Prognostic significance of additional cytogenetic aberrations in 733 de (2011) (0)
Refining prognosis in chronic lymphocytic leukemia with normal Fluorescence in situ hybridization results. (2023) (0)
Cytogenetic Studies of 539 Chronic Lymphocytic Leukemia (CLL) Patients. (2005) (0)
Intrachromosomal Amplification of Chromosome 21(iAMP21): Cytogenetic Characterisation and Outcome in Childhood B-Cell Precursor Acute Lymphoblastic Leukaemia (BCP-ALL). A Study On Behalf of the Ponte Di Legno International Childhood ALL Workshop (2012) (0)
Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates. (2022) (0)
39. Chronic lymphocytic leukemia with gain of 2p responds favorably to ibrutinib despite frequent co-occurrence with additional adverse cytogenetic markers (2021) (0)
CCTG on the world stage at ASCO 2017 (2020) (0)
Abstract 2260: Evaluating a rare t(X;14)(q28;q32) translocation reveals MTCP1 as a driving factor in chronic lymphocytic leukemia (2021) (0)
Abnormalities o f C hromosome B ands 1 3q12 t o 1 3q14 i n Childhood A cute L ymphoblastic L eukemia (2000) (0)
Correction: Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq (2021) (0)
Abstract 3083: The genetic landscape of Ph-like acute lymphoblastic leukemia (2014) (0)
with p53 mutations and deletions Alemtuzumab is an effective therapy for chronic lymphocytic leukemia (2013) (0)
Comparative evaluation of a new generation of fluorophores, Cy 35 and Cy2, by multicolor FISH (1995) (0)
myeloid leukemia: results of an international retrospective study Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute (2013) (0)
Long-Term Efficacy and Safety of Single-Agent Ibrutinib at 3 Years Follow-up in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia (CLL/SLL) (2015) (0)
Inferring clonal heterogeneity in cancer using SNP arrays and whole genome sequencing (2019) (0)
Treatment of Childhood T-Lineage Acute Lymphoblastic (1998) (0)
Gilteritinib (GILT) Monotherapy with Addition of Decitabine (DEC) in Non-Responders in Older Newly Diagnosed (ND) FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Having High and Low Variant Allele Frequency (VAF): A Phase 2/1b Sub-Study of the Beat AML Master Trial (2021) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Nyla A. Heerema?

Nyla A. Heerema is affiliated with the following schools:

Indiana University
Ohio State University
University of British Columbia
University of Southern California
Johns Hopkins University

Nyla A. Heerema's Academic­Influence.com Rankings

Why Is Nyla A. Heerema Influential?

Nyla A. Heerema's Published Works

Published Works

What Schools Are Affiliated With Nyla A. Heerema?

Nyla A. Heerema's AcademicInfluence.com Rankings